4 ms·

This is of course one of those things that is interesting, but of no relevance to the future of your life and life span. If all goes well in the research space,

This is of course one of those things that is interesting, but of no relevance to the future of your life and life span. If all goes well in the research space, the pace at which rejuvenation therapies arrive over the next 20 years will be the dominant driver of your mortality rate for the rest of your life - even just one narrow treatment after the SENS model capable of repairing one form of cellular damage that contributes to aging should have considerably more impact than exercise or calorie restriction.

ekianjo 11y ago
> which rejuvenation therapies arrive over the next 20 years will be the dominant driver of your mortality rate for the rest of your life I think you are being overly optimistic. Within 20 years I don't think there will be much change in that field, because you'll need clinical trials, proof of safety and so on, and if it's not ready right now in terms of what needs to happen conceptually and at the lab scale level, we already know it won't be on the market in 10-15 years from now.
- gwern 11y ago
  If it was up to the US, maybe things would be that slow, but I think you are not properly appreciating how fast CRISPR is advancing. The CEO of BioViva has already injected herself with edits relating to telomeres, and it's about ready for embryo editing: the main barrier was off-target mutations (this was the problem with the Chinese embryo editing last year), and that has effectively been solved with some tweaks to the enzyme to yield ~0% off-target mutations. As stem cell treatments show, the bioconservatives in the USA can try to slow things down, but the USA is not the only place in the world with biomedical expertise these days.